NASDAQ:KALV

KalVista Pharmaceuticals Competitors

$24.05
+0.44 (+1.86 %)
(As of 04/21/2021 02:13 PM ET)
Add
Compare
Today's Range
$23.13
Now: $24.05
$24.40
50-Day Range
$23.12
MA: $29.09
$35.83
52-Week Range
$9.03
Now: $24.05
$45.00
Volume10,991 shs
Average Volume955,143 shs
Market Capitalization$584.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13

Competitors

KalVista Pharmaceuticals (NASDAQ:KALV) Vs. RCUS, CYRX, PBH, ALXO, ZNTL, and MDGL

Should you be buying KALV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to KalVista Pharmaceuticals, including Arcus Biosciences (RCUS), Cryoport (CYRX), Prestige Consumer Healthcare (PBH), ALX Oncology (ALXO), Zentalis Pharmaceuticals (ZNTL), and Madrigal Pharmaceuticals (MDGL).

Arcus Biosciences (NYSE:RCUS) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Earnings and Valuation

This table compares Arcus Biosciences and KalVista Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million159.00$-84,710,000.00($1.93)-17.44
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66

KalVista Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

60.6% of Arcus Biosciences shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 19.7% of Arcus Biosciences shares are held by company insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Arcus Biosciences and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Analyst Ratings

This is a summary of current recommendations and price targets for Arcus Biosciences and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
KalVista Pharmaceuticals00603.00

Arcus Biosciences currently has a consensus target price of $51.50, indicating a potential upside of 53.05%. KalVista Pharmaceuticals has a consensus target price of $50.1667, indicating a potential upside of 107.47%. Given KalVista Pharmaceuticals' higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Arcus Biosciences.

Summary

Arcus Biosciences beats KalVista Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both transportation companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Volatility & Risk

Cryoport has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cryoport and KalVista Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million69.64$-18,330,000.00($0.55)-94.24
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66

Cryoport has higher revenue and earnings than KalVista Pharmaceuticals. Cryoport is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

88.3% of Cryoport shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 11.5% of Cryoport shares are held by company insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Cryoport and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Analyst Ratings

This is a summary of current recommendations and price targets for Cryoport and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
KalVista Pharmaceuticals00603.00

Cryoport currently has a consensus target price of $72.00, indicating a potential upside of 38.94%. KalVista Pharmaceuticals has a consensus target price of $50.1667, indicating a potential upside of 107.47%. Given KalVista Pharmaceuticals' higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Cryoport.

Summary

Cryoport beats KalVista Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Prestige Consumer Healthcare (NYSE:PBH) and KalVista Pharmaceuticals (NASDAQ:KALV) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Volatility & Risk

Prestige Consumer Healthcare has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and KalVista Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million2.37$142.28 million$2.9615.45
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66

Prestige Consumer Healthcare has higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Prestige Consumer Healthcare and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare17.03%13.76%4.80%
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Analyst Ratings

This is a summary of current recommendations and price targets for Prestige Consumer Healthcare and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare03302.50
KalVista Pharmaceuticals00603.00

Prestige Consumer Healthcare currently has a consensus target price of $87.60, indicating a potential upside of 91.52%. KalVista Pharmaceuticals has a consensus target price of $50.1667, indicating a potential upside of 107.47%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Prestige Consumer Healthcare.

ALX Oncology (NASDAQ:ALXO) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares ALX Oncology and KalVista Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/AN/AN/AN/A
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66

ALX Oncology has higher earnings, but lower revenue than KalVista Pharmaceuticals.

Profitability

This table compares ALX Oncology and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ALX OncologyN/AN/AN/A
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Analyst Ratings

This is a summary of current recommendations and price targets for ALX Oncology and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ALX Oncology00703.00
KalVista Pharmaceuticals00603.00

ALX Oncology currently has a consensus target price of $90.6667, indicating a potential upside of 62.19%. KalVista Pharmaceuticals has a consensus target price of $50.1667, indicating a potential upside of 107.47%. Given KalVista Pharmaceuticals' higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than ALX Oncology.

Insider and Institutional Ownership

73.5% of ALX Oncology shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 18.0% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

KalVista Pharmaceuticals (NASDAQ:KALV) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Earnings & Valuation

This table compares KalVista Pharmaceuticals and Zentalis Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Zentalis Pharmaceuticals has lower revenue, but higher earnings than KalVista Pharmaceuticals.

Profitability

This table compares KalVista Pharmaceuticals and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KalVista Pharmaceuticals-229.45%-47.45%-41.84%
Zentalis PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for KalVista Pharmaceuticals and Zentalis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KalVista Pharmaceuticals00603.00
Zentalis Pharmaceuticals00703.00

KalVista Pharmaceuticals presently has a consensus price target of $50.1667, indicating a potential upside of 107.47%. Zentalis Pharmaceuticals has a consensus price target of $57.00, indicating a potential upside of 7.49%. Given KalVista Pharmaceuticals' higher possible upside, equities analysts plainly believe KalVista Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Institutional and Insider Ownership

90.2% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 18.0% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

KalVista Pharmaceuticals (NASDAQ:KALV) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Earnings & Valuation

This table compares KalVista Pharmaceuticals and Madrigal Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KalVista Pharmaceuticals$12.69 million46.07$-29,120,000.00($1.64)-14.66
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-23.72

KalVista Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

KalVista Pharmaceuticals has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares KalVista Pharmaceuticals and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
KalVista Pharmaceuticals-229.45%-47.45%-41.84%
Madrigal PharmaceuticalsN/A-47.64%-43.21%

Analyst Recommendations

This is a breakdown of current ratings and price targets for KalVista Pharmaceuticals and Madrigal Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
KalVista Pharmaceuticals00603.00
Madrigal Pharmaceuticals03702.70

KalVista Pharmaceuticals presently has a consensus price target of $50.1667, indicating a potential upside of 107.47%. Madrigal Pharmaceuticals has a consensus price target of $167.60, indicating a potential upside of 29.64%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe KalVista Pharmaceuticals is more favorable than Madrigal Pharmaceuticals.

Institutional and Insider Ownership

90.2% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. 18.0% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

KalVista Pharmaceuticals beats Madrigal Pharmaceuticals on 10 of the 13 factors compared between the two stocks.


KalVista Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.65+5.1%$2.26 billion$15 million-17.62
Cryoport logo
CYRX
Cryoport
1.7$51.83+4.3%$2.26 billion$33.94 million-89.36
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.74+1.3%$2.25 billion$963.01 million14.20
ALX Oncology logo
ALXO
ALX Oncology
1.9$55.90+2.6%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$53.03+3.5%$2.10 billionN/A0.00Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.28+2.3%$2.02 billionN/A-11.68News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.75+0.3%$2.02 billion$64.19 million-10.78Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.73+3.5%$1.98 billion$103.54 million-20.10
Amarin logo
AMRN
Amarin
1.6$5.03+1.6%$1.95 billion$429.76 million-100.58
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.47+2.4%$1.91 billion$410,000.00-5.97
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.73+5.8%$1.89 billionN/A-19.97Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.46+0.5%$1.87 billion$256.58 million-7.84
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$57.95+0.1%$1.86 billionN/A-24.66
Kura Oncology logo
KURA
Kura Oncology
1.6$27.78+0.6%$1.85 billionN/A-17.04News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.35+0.2%$1.81 billion$26.87 million-13.27Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.09+2.4%$1.79 billion$34.51 million-17.17
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05+0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.65+5.9%$1.76 billion$16.98 million-36.96Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.82+1.5%$1.72 billion$428.41 million15.68Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.73+1.0%$1.70 billion$1.63 billion13.98
Generation Bio logo
GBIO
Generation Bio
1.8$30.85+2.5%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.06+1.6%$1.63 billion$145.97 million-7.31
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.54+2.7%$1.62 billion$392.76 million13.09Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.98+5.9%$1.62 billionN/A-6.75Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.36+1.7%$1.58 billion$2.34 million-9.90
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82+1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$36.00+7.7%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.87+2.5%$1.52 billion$175.34 million-15.22Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.26+3.2%$1.51 billion$320,000.00-8.34
uniQure logo
QURE
uniQure
1.7$31.98+1.7%$1.46 billion$7.28 million-8.48Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.50+2.4%$1.46 billion$82.27 million-18.29
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.65+3.3%$1.44 billionN/A-3.21Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$62.28+1.7%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.17+0.4%$1.42 billion$73.41 million-4.69News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.64+2.2%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.40+6.4%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89+0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.30+2.9%$1.37 billion$19.89 million-13.35
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.28+3.0%$1.37 billion$4.23 million-20.21Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$35.52+5.5%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.75+2.1%$1.30 billion$2.91 billion-8.46
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.67+7.3%$1.28 billionN/A-144.46Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.61+0.3%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.58+3.9%$1.22 billion$29.54 million-7.32News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.10+1.0%$1.21 billion$261.02 million6.17News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$33.06+2.3%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.33+1.9%$1.18 billionN/A0.00Analyst Report
Insider Selling
News Coverage
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.52+3.3%$1.17 billion$230,000.00-12.80
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.90+4.5%$1.16 billion$59.70 million-199.00
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.